SGT-53, A NOVEL NANOMEDICINE THAT CROSSES THE BBB, AUGMENTS IMMUNOTHERAPEUTIC RESPONSE IN PEDIATRIC BRAIN CANCERS

Children'S Research Institute, Washington DC

Investigators